BaseSNAP™
Sensitive Nucleic Acid Purification kit
The BaseSNAP™ DNA and RNA Extraction kit is intended for automated extraction of RNA/DNA from saliva or oropharyngeal and nasopharyngeal swabs. The extraction kit is our low cost, high yield solution allowing for high-throughput processing of samples. The BaseSnap™ DNA and RNA Extraction kit can be used widely in the following fields: diagnostics, genomics research, disease detection, food safety and forensic identification, etc.
Product Details
Reference number:
3054, 3055, 3057
Intended Use
The BaseSNAP™ DNA and RNA Extraction kit is intended for automated extraction of RNA/DNA
from saliva or oropharyngeal and nasopharyngeal swabs. The extraction kit is our low cost, high
yield solution allowing for high-throughput processing of samples. The BaseSnap™ DNA and RNA
Extraction kit can be used widely in the following fields: diagnostics, genomics research, disease
detection, food safety and forensic identification, etc.
Magnetic beads binds the negatively charged nucleic acid. The Magnetic beads carrying nucleic acids
are magnetized, transferred and released through the specialized magnetic rods during the process
of nucleic acid extraction, which accomplishes automated extraction.
Product Specifications
BaseSNAP™ Sensitive Nucleic Acid Purification kit
Sample types Swab and other
Format Single
Ref. No.: 3054
BaseSNAP™ Sensitive Nucleic Acid Purification kit
Sample types Swab and other
Format 5 plates of 16 reactions
Ref. No.: 3055
BaseSNAP™ Sensitive Nucleic Acid Purification kit
– minus eluent Sample types Swab and other
Format 5 plates of 16 reactions
Ref. No.: 3057
Instructions For Use
For the latest version of the catalogue – Click here –
Assisting the Stratification of Lymphomas
The PlentiPlex™ MYD88 L265P assay is intended for in vitro diagnosis of the leucine to proline mutation in codon 265 of the Myeloid differentiation primary response 88 protein (MYD88 L265P) in genomic DNA (gDNA) samples. The obtained results of the PlentiPlex™ MYD88 L265P assay are intended for assisting in the discrimination between patients with Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM) and other non-Hodgkin lymphomas.
